Chronic Pain

This is our library on scientific research related to CBD, the Endocannabinoid System, other cannabinoids and Chronic Pain. Below you will find a list of conditions for which there are one or more scientific studies of CBD. The source of these scientific studies relates primarily to PubMed, an online service of the U.S. National Library of Medicine.

Important: The studies that are listed by PubMed are for the most part preclinical research. These relate in most cases to animal experiments with isolated CBD (pure CBD) and not fully extracted CBD extract. Although mammals have cell receptors that respond to cannabinoid compounds, the data collected from animal studies are not always 1: 1 applicable to humans. Always check with your physician before starting a new dietary supplement program. Learn more at: The Basics of CBD Oils and Cannabis as a Therapeutic Agent

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
Cannabinoids for neuropathic pain
Cannabinoids in the management of difficult to treat pain  
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
Cannabis, pain, and sleep: Sativex Clinical Trials
CBD & THC interactions on acute pain and locomotor activity
CBD Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats
Marijuana extract helps prevent chemo pain
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability ofTHC:CBD extract and THC extract in patients with intractable cancer-related pain
Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action  
Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
Pot users less likely to take painkillers
Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
Sativex successfully treats neuropathic pain characterised by allodynia: clinical trial
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain  
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation

Send this to a friend